Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
An investigation conducted by the U.S. House of Representatives shows Emergent was forced to destroy nearly 400 million doses of the vaccine. The company disputes the report’s claim.
Jacqueline Shea will take over as the new CEO and announced plans to discontinue its Phase III Innovate trial to prioritize its heterologous booster strategy for COVID-19.
The revised PDUFA action date for miglustat is August 29, 2022, while the new date for cipaglucosidase alfa is October 29, 2022. Amicus expects the agency to approve the applications together.
AstraZeneca and Sanofi’s Phase-III and Phase-IIb clinical trials investigating the efficacy of nirsevimab shows 79.5% efficacy in the prevention of lower respiratory tract infections.
Genentech (Roche) reported Wednesday that its Phase III SKYSCRAPER-01 trial failed to meet its co-primary endpoint of progression-free survival (PFS).
BioSpace spoke with industry experts to find out the differences between working in pharma and biotech and how to know if a pharma company is right for you.
ICER recommended two out of three outpatient treatments for COVID-19 in today’s market, singling out molnupiravir as having inadequate evidence that it is better than symptomatic care.
Nuvig plans to use its funding to advance its lead molecule, complete some pre-IND enabling studies and move the molecule to the clinic to begin Phase I studies.
Bristol Myers Squibb announced it is extending and expanding its strategic partnership with Evotec in targeted protein degradation, marking its second protein degradation deal this month.
Cortexyme has entered into a deal to acquire Novosteo. Once the deal is finalized, the companies will enter the rare disease space and operate under the name Quince Therapeutics.
Current COVID-19 booster shots have a problem: they last only about four months and appear to have limited efficacy in a vaccinated population. Clearly, a more durable approach is needed.
Despite posting its first profitable quarter as a commercial stage company, shares of Novavax plunged 20% in Tuesday trading due to the slower-than-expected rollout of its COVID-19 vaccine.
PRESS RELEASES
Head-to-Head Study Highlights Rocbrutinib as the World’s First Fourth-Generation Dual Covalent and Non-Covalent BTK Inhibitor Designed to Overcome Resistance Mutations
Corporate Treasury Positioned with Cash and Liquid Equity Holdings to Seed, Incubate and Accelerate New and Existing Operations